Toronto Dominion Bank grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 58.6% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 666,424 shares of the biopharmaceutical company's stock after acquiring an additional 246,183 shares during the period. Toronto Dominion Bank owned about 0.05% of Gilead Sciences worth $45,723,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also made changes to their positions in GILD. Fred Alger Management LLC raised its position in Gilead Sciences by 9.8% in the second quarter. Fred Alger Management LLC now owns 27,357 shares of the biopharmaceutical company's stock valued at $1,877,000 after purchasing an additional 2,442 shares during the period. Wescott Financial Advisory Group LLC purchased a new stake in shares of Gilead Sciences in the second quarter worth about $231,000. Point72 Asset Management L.P. grew its stake in shares of Gilead Sciences by 43.2% in the second quarter. Point72 Asset Management L.P. now owns 512,125 shares of the biopharmaceutical company's stock valued at $35,137,000 after buying an additional 154,525 shares in the last quarter. Insigneo Advisory Services LLC raised its holdings in shares of Gilead Sciences by 1.7% during the 2nd quarter. Insigneo Advisory Services LLC now owns 8,830 shares of the biopharmaceutical company's stock valued at $661,000 after buying an additional 148 shares during the period. Finally, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lifted its position in Gilead Sciences by 60.1% during the 2nd quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 238,870 shares of the biopharmaceutical company's stock worth $16,389,000 after acquiring an additional 89,632 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.
GILD has been the subject of several recent research reports. Raymond James raised shares of Gilead Sciences from a "market perform" rating to an "outperform" rating and set a $93.00 price objective for the company in a research report on Monday, July 8th. Needham & Company LLC reaffirmed a "hold" rating on shares of Gilead Sciences in a report on Thursday, August 15th. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $70.00 price target on shares of Gilead Sciences in a research note on Monday, September 16th. Evercore ISI raised shares of Gilead Sciences to a "strong-buy" rating in a research report on Friday, August 9th. Finally, Robert W. Baird reaffirmed a "neutral" rating and set a $80.00 target price on shares of Gilead Sciences in a research report on Thursday, June 20th. Twelve research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, Gilead Sciences has a consensus rating of "Moderate Buy" and an average target price of $82.06.
Check Out Our Latest Stock Analysis on Gilead Sciences
GILD stock opened at $82.21 on Thursday. The firm has a market cap of $102.35 billion, a price-to-earnings ratio of 228.36, a PEG ratio of 2.91 and a beta of 0.18. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $87.86. The firm has a fifty day moving average price of $77.46 and a two-hundred day moving average price of $71.37. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.14 and a quick ratio of 0.95.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating analysts' consensus estimates of $1.61 by $0.40. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. The business had revenue of $6.95 billion during the quarter, compared to the consensus estimate of $6.64 billion. Research analysts predict that Gilead Sciences, Inc. will post 3.78 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, September 27th. Investors of record on Friday, September 13th will be issued a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 3.75%. The ex-dividend date of this dividend is Friday, September 13th. Gilead Sciences's dividend payout ratio (DPR) is 855.56%.
In other Gilead Sciences news, insider Johanna Mercier sold 5,490 shares of the firm's stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total value of $406,150.20. Following the sale, the insider now directly owns 114,979 shares in the company, valued at $8,506,146.42. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the firm's stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $68.63, for a total transaction of $137,260.00. Following the transaction, the insider now owns 96,380 shares of the company's stock, valued at approximately $6,614,559.40. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Johanna Mercier sold 5,490 shares of the company's stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total transaction of $406,150.20. Following the completion of the sale, the insider now directly owns 114,979 shares of the company's stock, valued at $8,506,146.42. The disclosure for this sale can be found here. Insiders sold 36,847 shares of company stock worth $3,002,940 in the last 90 days. 0.16% of the stock is currently owned by company insiders.
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.